Covington, Georgia—In a notable case involving ethylene oxide (EtO), a jury awarded $20 million in compensatory damages to a plaintiff who alleged that his exposure to the chemical resulted in a diagnosis of non-Hodgkin lymphoma. The decision came after a trial focused on the sterilization practices of C.R. Bard, which operates a medical equipment sterilization facility in Covington. The plaintiff, who drove a truck near the facility, claimed he was exposed to harmful levels of EtO while making regular pickups and living just a mile and a half away from the plant. His battle with cancer led to extensive medical treatment, including ten rounds of chemotherapy and a stem-cell transplant after being diagnosed in 2017 at age 68.
The trial is one of many bringing attention to the health risks associated with EtO, a versatile industrial solvent used primarily to sterilize equipment that cannot withstand high temperatures. The substance is also pivotal in the production of various chemicals, such as glycol and detergents. Concerns about its potential link to certain cancers have spurred numerous lawsuits and regulatory scrutiny of companies utilizing EtO in their operations.
Historically, this case is part of a broader wave of litigation surrounding EtO exposure. In September 2022, a jury awarded $263 million to plaintiffs in Illinois over ethylene oxide emissions from Sterigenics’ facility in Willowbrook. This landmark ruling was followed by a mixed outcome in subsequent Illinois trials, including a defense verdict in another case. Despite this, Sterigenics ultimately settled numerous claims related to the Willowbrook plant for a total of $408 million. By contrast, a recent Pennsylvania trial found B. Braun Manufacturing Inc. not liable for cancer claims linked to its Allentown facility.
A bellwether trial in Colorado earlier this year marked a significant development when a jury ruled in favor of Terumo BCT Inc. The case, which spanned six weeks, involved four female plaintiffs who alleged cancer resulting from emissions from Terumo’s Lakewood plant. The jury found that Terumo did not act negligently and, therefore, did not consider damages or causation, leaving many questions unresolved.
Dozens of similar claims remain pending against Terumo, with plaintiffs’ attorneys reportedly filing new cases even during the trial. Legal experts indicate that heightened trial activity related to EtO is likely, as more cases continue to emerge across several states, including expected litigation in California, where many cases are still under review.
As other states prepare for their own trials, the recent verdict in Georgia may encourage other victims of alleged EtO exposure to seek legal counsel. Legal analysts suggest this outcome could lead to a surge of advertising from plaintiff firms looking to attract new clients claiming cancer due to proximity to EtO plants, mirroring trends seen in previous mass tort cases.
With hundreds of claims still pending against various companies, including C.R. Bard, it is anticipated that more trials will unfold in the coming months, drawing public and media attention to the implications of ethylene oxide exposure on community health.
The article was automatically generated by OpenAI, and the facts, circumstances, and individuals mentioned may be inaccurate. Requests for corrections, removal, or retraction can be made by contacting contact@publiclawlibrary.org.